MedTrace Logo

A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

NCT00370890 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2022-02-17

No results posted yet for this study

Summary

The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.

Conditions

  • Nasopharyngeal Cancer

Interventions

DRUG

Adjuvant chemotherapy (gemcitabine and cisplatin)

Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles

Sponsors & Collaborators

  • Hong Kong Nasopharyngeal Cancer Study Group Limited

    collaborator OTHER

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Anthony TC Chan, MD, FRCP · Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

  • Roger KC Ngan, FRCR · Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-04
Primary Completion
2021-10-26
Completion
2021-10-26

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370890 on ClinicalTrials.gov